Decoding, Mapping, and Designing: A New Paradigm for Harnessing Umbilical Cord Mesenchymal Stem Cell Heterogeneity in Obstetric Precision Therapy.

Umbilical cord mesenchymal stem cells (UC-MSCs) are attractive candidates for obstetric regenerative medicine because of their accessibility, proliferative capacity, and broad immunomodulatory repertoire. Yet clinical translation remains constrained by inter-donor and intra-product heterogeneity, unstable potency readouts, and the absence of a reproducible framework that links molecular states to disease-specific therapeutic needs. In this revised review, we refine the "Decode-Map-Design" paradigm into a structured translational workflow. "Decode" integrates single-cell and spatial omics, donor metadata, and orthogonal potency assays to define operational functional states rather than assuming fixed subtypes. "Map" aligns these states with dominant pathobiologic modules in obstetric disorders-including immune dysregulation, vascular injury, metabolic stress, and extracellular matrix remodeling-to enable mechanism-based matching. "Design" then uses atlas-guided isolation, microenvironmental priming, genetic engineering, and standardized cell-free formulation to build products with predefined release criteria. We further incorporate the principal barriers that currently limit implementation, including marker instability across laboratories, culture-driven state drift, assay standardization, GMP scalability, regulatory classification, cost, and the paucity of subtype-guided clinical data. A worked preeclampsia case study is provided to illustrate an end-to-end pipeline from atlas discovery to early-phase trial design. We argue that UC-MSC heterogeneity should be treated neither as noise nor as a guarantee of efficacy, but as a measurable and engineerable source of therapeutic optionality. The framework remains hypothesis-generating, and requires validation in human-relevant models and prospective clinical studies, but it offers a practical roadmap for converting heterogeneous UC-MSC products into safer and more precise obstetric therapeutics.